Editorial: Neuroprotection and Disease Modification in Parkinson’s Disease

OTERO-LOSADA, MATILDE; GUBELLINI, PAOLO; CAPANI, FRANCISCO; PEREZ-LLORET, SANTIAGO

Frontiers in Pharmacology

Frontiers Media S.A.

Lugar: Florida; Año: 2021 vol. 12

Parkinson’s disease (PD) is the second prevailing neurodegenerative disease in the world after Alzheimer’s. It affects about 1% of adults over 65 years old, with a growing incidence as the global population ages. Bradykinesia, tremor, and rigidity are the typical symptoms of PD. Yet, a myriad of non-motor symptoms like mood, sleep, and autonomic alterations impair patients’ life quality. Current treatments focus on PD symptoms but do not slow disease progression, and no preventing treatment is yet available against PD.Identifying drugs and therapies that can change the course of PD is one of the most critical yet unmet needs in current pharmacological approaches to this disease. Past efforts have been ineffective in identifying these desired pharmaceuticals. Therefore, basic studies aiming at testing the potential neuroprotective properties of new molecules are needed.This Research Topic focuses on addressing new pharmacological neuroprotective and disease-modifying strategies for PD, their target pathways, and their effects on humans. The goal is to contribute with updated information to developing new therapeutic strategies to prevent PD and halt its progression.The topics covered are as follows:.....